EFS by cytokine in MER subgroups. The EFS by serum IL-12 levels in patients in the MER cohort who were observed or received rituximab monotherapy (A). The EFS by serum IL-2R (B), CXCL9 (C), and IL-1RA (D) levels in patients in the MER cohort who were treated with chemotherapy.